ACRS News and Press, Aclaris Therapeutics Inc. From 07/07/20

Aclaris Therapeutics has submitted an Investigational New Drug application to the FDA for ATI-1777, a topical "soft" Janus kinase 1/3 inhibitor, for moderate to severe atopic dermatitis (AD). More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Read more ...

WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Applic...

Carver Bancorp (NASDAQ: CARV ) +232% . More news on: Carver Bancorp, Inc., Urban One, Inc., Energous Corporation, Stocks on the move, , Read more ...

Thinly traded nano cap Aclaris Therapeutics (NASDAQ: ACRS ) rockets  83%  premarket on robust volume in reaction to its announcement that the FDA has signed off an an investigator-initiated Phase 2a study evaluating lead candidate ATI-450 (on top of standard-of-care treatment) ...

FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19 Aclaris Supports Investigator-Initiated Clinical Trial Sponsored by the University of Kansas Medical Center ATI-450 Inhibits Multiple Key Inflammatory Cytokines WAYNE, Pa., June 17, 2020 (GLOBE NEWSWIRE) -- A...

A coalition of 51 attorneys general in the U.S. has filed an antitrust complaint  in federal court against 26 companies making generic dermatology drugs and 10 executives at these firms claiming wide-spread price-fixing, marketing allocating and bid-rigging related to over 80 different...

WAYNE, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced the publication of an abstract at the 2020 European Congress o...

WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Wednes...

Aclaris Therapeutics (NASDAQ: ACRS ): Q1 GAAP EPS of -$0.37 beats by $0.01 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Projected Cash Runway into the First Quarter of 2022 Borrowed $11 Million from Term Loan Facility WAYNE, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today an...